Alnylam Pharmaceuticals, Inc. (ALNY) vs ResMed Inc. (RMD)
A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and ResMed Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
ALNY
Alnylam Pharmaceuticals, Inc.
$240.98HealthcareDelayed quote: Sep 18, 2026, 2:15 PM EDT
RMD
ResMed Inc.
$227.92HealthcareDelayed quote: Sep 18, 2026, 2:15 PM EDT
Total return — ALNY vs RMD
growth of $100 · dividends reinvested · last 10yALNY +242.9% (+13.1%/yr)RMD +271.7% (+14.0%/yr)RMD compounded faster over this window
ALNY RMD
ALNY vs RMD: by the numbers
- •RMD is the larger company ($33.06B vs $32.25B market cap).
- •RMD trades at the lower trailing earnings multiple (21.92 vs 40.71 P/E), one valuation lens rather than an overall verdict.
- •RMD converts more revenue to profit (26.94% vs 16.82% net margin).
- •ALNY grew revenue faster over the past five years (47.53% vs 12.08% CAGR).
- •RMD pays a dividend (1.10% yield), while ALNY has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | ALNY | RMD |
|---|---|---|
| P/E ratio | 40.71 | 21.92 |
| Forward P/E | 36.11 | 18.85 |
| P/S ratio | 6.71 | 5.85 |
| P/B ratio | 23.81 | 5.02 |
| EV / EBITDA | 30.17 | 15.51 |
| FCF yield | 1.68% | N/A |
Profitability
| Metric | ALNY | RMD |
|---|---|---|
| Gross margin | 79.72% | 61.16% |
| Operating margin | 20.81% | 33.48% |
| Net margin | 16.82% | 26.94% |
| ROE | 59.67% | 23.13% |
| ROIC | 24.71% | 19.18% |
Dividends
| Metric | ALNY | RMD |
|---|---|---|
| Dividend yield | N/A | 1.10% |
| Payout ratio | N/A | 23.08% |
Growth (annualized)
| Metric | ALNY | RMD |
|---|---|---|
| Revenue CAGR (5Y) | 47.53% | 12.08% |
| EPS CAGR (5Y) | N/A | 26.14% |
| FCF CAGR (5Y) | N/A | 21.62% |
| Total return CAGR (5Y) | 5.58% | -5.02% |
Frequently asked
- Which has the lower trailing P/E, ALNY or RMD?
- RMD has the lower trailing P/E: ALNY trades at 40.71 and RMD at 21.92. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, ALNY or RMD?
- Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus RMD at 12.08%.
- Does ALNY or RMD pay a bigger dividend?
- RMD pays a dividend (1.10% yield), while ALNY has no payments in the available dividend history.
- Is ALNY or RMD more profitable?
- RMD runs the higher net margin — ALNY at 16.82% versus RMD at 26.94%.
- How have ALNY and RMD total returns compared?
- Over the past 10 years, ALNY delivered 13.54% and RMD delivered 14.06% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Alnylam Pharmaceuticals P/E ratioResMed P/E ratioResMed dividend yieldAlnylam Pharmaceuticals ROEResMed ROEAlnylam Pharmaceuticals operating marginResMed operating marginAlnylam Pharmaceuticals revenue growthResMed revenue growthAlnylam Pharmaceuticals free cash flowResMed free cash flow
Alnylam Pharmaceuticals & ResMed appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.